Inogen Inc (INGN)
8.81
+0.56
(+6.79%)
USD |
NASDAQ |
May 24, 16:00
8.78
-0.03
(-0.34%)
After-Hours: 20:00
Inogen Research and Development Expense (Annual): 20.84M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 20.84M |
| December 31, 2022 | 21.94M |
| December 31, 2021 | 16.58M |
| December 31, 2020 | 14.08M |
| December 31, 2019 | 9.401M |
| December 31, 2018 | 7.029M |
| December 31, 2017 | 5.313M |
| Date | Value |
|---|---|
| December 31, 2016 | 5.113M |
| December 31, 2015 | 4.18M |
| December 31, 2014 | 2.977M |
| December 31, 2013 | 2.398M |
| December 31, 2012 | 2.262M |
| December 31, 2011 | 1.789M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
9.401M
Minimum
2019
21.94M
Maximum
2022
16.57M
Average
16.58M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Oragenics Inc | 15.49M |
| Palatin Technologies Inc | 22.63M |
| vTv Therapeutics Inc | 13.60M |
| G1 Therapeutics Inc | 43.71M |
| Vera Therapeutics Inc | 78.22M |